A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

Bristol-Myers Squibb28,000 enrolled

Overview

A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related hospital readmissions among hospitalized VTE patients treated with apixaban or warfarin, with or without low molecular weight heparin (LMWH)

Study Type

OBSERVATIONAL

Enrollment

28,000

Conditions

Venous Thromboembolism (VTE)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have a primary diagnosis of VTE identified by ICD-9-CM or ICD-10 codes from the Premier Hospital database between 01-Aug-2014 and 31-May-2016 * Age 18 years or older as of index hospitalization with VTE diagnosis * Patients will be required to have received apixaban or warfarin with or without LMWH (index drugs) during the index hospitalizations Exclusion Criteria: * Received both apixaban and warfarin during the index hospitalization. This exclusion criterion will allow to cleanly group patients into the apixaban and warfarin usage cohorts. * Received any other Direct oral anticoagulants (DOAC) including rivaroxaban, dabigatran, and edoxaban during the index hospitalization * Have any primary or secondary diagnosis code for Atrial fibrillation/Atrial flutter (AF/AFL), or pregnancy, or records of inferior vena cava filter (IVCF) usage during the index hospitalizations or the baseline periods. * Patients transferred from other facilities Other protocol-defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Flemington, New Jersey, United States

Outcomes

Primary Outcomes

Hospital Length of stay (LOS)

Time frame: During the index hospitalization (Up to 30 days)

Hospital cost

Time frame: During the index hospitalization (Up to 30 days)

Secondary Outcomes

Proportion of patients with major bleeding (MB)-related hospital readmissions

Time frame: During 1 month after the index hospitalization

Proportion of patients with clinically relevant bleeding (CRB)-related hospital readmissions

Time frame: During 1 month after the index hospitalization

Proportion of patients with any bleeding-related hospital readmissions

Time frame: During 1 month after the index hospitalization

Proportion of patients with VTE-related hospital readmissions

Time frame: During 1 month after the index hospitalization

Proportion of patients with combined VTE- or MB-related hospital readmissions

Time frame: During 1 month after the index hospitalization

Proportion of patients with all-cause hospital readmissions

Time frame: During 1 month after the index hospitalization

Hospital Length of stay (LOS) for major bleeding-related hospital readmissions